Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5313074 | 0.98 | CYP3A4 (0.48) | CYP3A4ALOX15TSHRTP53SLC6A3 | |
| Hydrochloric Acid SCHEMBL10761065 | 0.97 | CYP3A4 (0.47) | CYP3A4ALOX15TSHRTP53SLC6A3 | |
| SCHEMBL25311978 | 0.79 | GRIN2D (0.49) | CYP3A4ALOX15TSHRTP53SLC6A3 | |
| SCHEMBL5153683 | 0.78 | GRIN2D (0.46) | CYP3A4ALOX15TSHRTP53SLC6A3 | |
| Hydrochloric Acid SCHEMBL5308749 | 0.78 | GRIN2D (0.44) | CYP3A4ALOX15TSHRTP53SLC6A3 | |
| Hydrochloric Acid SCHEMBL5310517 | 0.77 | GRIN2D (0.47) | CYP3A4ALOX15TSHRTP53SLC6A3 | |
| SCHEMBL25310650 | 0.74 | GRIN2D (0.55) | SLC6A3SLC6A4SLC6A2GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL5313749 | 0.74 | OPRL1 (0.41) | CYP3A4ALOX15TSHRTP53SLC6A3 | |
| Hydrochloric Acid SCHEMBL10467321 | 0.73 | SLC6A3 (0.41) | CYP3A4ALOX15TSHRTP53SLC6A3 | |
| SCHEMBL2379038 | 0.72 | SLC6A4 (0.50) | CYP3A4ALOX15TSHRTP53SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653911-A2 | METHODS FOR TREATING METABOLIC SYNDROME | Abbott Laboratories (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005016269-A2 | METHODS FOR TREATING METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2005-02-24 | — | — | WO | claimed |
| JP-2002535273-A | — | — | 2002-10-22 | — | — | JP | claimed |
| EP-1150672-A1 | METHOD TO AID SMOKING CESSATION | KNOLL PHARMACEUTICAL COMPANY (US) | 2001-11-07 | — | — | EP | claimed |
| WO-2000043002-A1 | METHOD TO AID SMOKING CESSATION | KNOLL PHARMACEUTICAL COMPANY (US) | 2000-07-27 | — | — | WO | claimed |
| WO-2007041463-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1742624-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1620388-A1 | SIBUTRAMINE FREE BASE IN CRYSTALLINE FORM AND ITS PHARMACEUTICAL USE | Cipla Ltd. (IN) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005079851-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | SEPRACOR, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005072715-A1 | USE OF (S)-DIDESMETHYLSIBUTRAMINEFOR TREATING, PREVENTING AND MANAGING A SLEEP DISORDER | SEPRACOR INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2004099119-A1 | SIBUTRAMINE FREE BASE IN CRYSTALLINE FORM AND ITS PHARMACEUTICAL USE | CIPLA LIMITED (IN) | 2004-11-18 | — | — | WO | disclosed |
| EP-1320360-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF SEXUAL DYSFUNCTION | Sepracor Inc. (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002022114-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF SEXUAL DYSFUNCTION | SEPRACOR INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-1150672-A1 | METHOD TO AID SMOKING CESSATION | KNOLL PHARMACEUTICAL COMPANY (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001051453-A1 | RACEMIC AND OPTICALLY PURE METABOLITES OF SIBUTRAMINE, THEIR PREPARATION, COMPOSITIONS COMPRISING THEM AND THEIR USE AS DOPAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-1107746-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS | Sepracor Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000043002-A1 | METHOD TO AID SMOKING CESSATION | KNOLL PHARMACEUTICAL COMPANY (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000010551-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0828484-A1 | USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY | Knoll AG (DE) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996038134-A1 | USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY | KNOLL AG (DE) | 1996-12-05 | — | — | WO | disclosed |